DK2842568T3 - Farmaceutisk sammensætning til behandling og/eller forebyggelse af type i-diabetes og anvendelse deraf - Google Patents

Farmaceutisk sammensætning til behandling og/eller forebyggelse af type i-diabetes og anvendelse deraf Download PDF

Info

Publication number
DK2842568T3
DK2842568T3 DK13785267.9T DK13785267T DK2842568T3 DK 2842568 T3 DK2842568 T3 DK 2842568T3 DK 13785267 T DK13785267 T DK 13785267T DK 2842568 T3 DK2842568 T3 DK 2842568T3
Authority
DK
Denmark
Prior art keywords
insulin
sequence
dex
cells
group
Prior art date
Application number
DK13785267.9T
Other languages
English (en)
Inventor
Bin Wang
Guoxing Zheng
Shuang Geng
Yizhong Wang
Qingling Yu
Original Assignee
Beijing Advaccine Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Advaccine Biotechnology Co Ltd filed Critical Beijing Advaccine Biotechnology Co Ltd
Application granted granted Critical
Publication of DK2842568T3 publication Critical patent/DK2842568T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (8)

1. Sammensætning egnet til behandling og/eller forebyggelse af type 1-diabetes (TID), der omfatter sammensætning 1) eller 2) som den aktive ingrediens: 1) Blanding af proteinantigen og immunundertrykkende middel(er), hvor vægtforholdet mellem proteinantigenet og immunundertrykkende middel(er) er 1:1 til 10:1, 2) Blanding af epitoppeptider af proteinantigenet og immunundertrykkende middel(er), hvor vægtforholdet mellem epitoppeptiderne og immunundertrykkende middel(er) er 1:1, hvor proteinantigenet er insulin eller et fragment deraf, og hvor det immunundertrykkende middel er valgt fra gruppen bestående af dexamethason (Dex), tacrolimus (FK506), cyclosporin (CsA), prednison (Pred), methylprednisolon (MP) og kombinationer deraf.
2. Sammensætning ifølge krav 1, hvor det immunundertrykkende middel er dexamethason (Dex).
3. Sammensætning ifølge krav 1, hvor sekvensen af insulin og fragmenter deraf er menneske-, hunde- eller katte-afledte, og epitoppeptiderne er afledt fra nativt menneske-, katte- og hundeprotein eller syntetiseres kemisk in vitro.
4. Sammensætning ifølge krav 3, hvor den anførte epitopsekvens fra insulin refererer til sekvens 1 eller sekvens 2 eller sekvens 3 eller sekvens 12 eller sekvens 13; det anførte epitoppeptid fra hundeinsulin henviser til sekvens 4 eller sekvens 5 eller sekvens 12 eller sekvens 13; det anførte epitoppeptid fra katteinsulin henviser til sekvens 6 eller sekvens 7 eller sekvens 12 eller sekvens 13.
5. Sammensætning ifølge krav 1-4 til anvendelse i en fremgangsmåde til behandling af type 1 diabetes og/eller forebyggelse.
6. Sammensætning ifølge krav 1-5 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af TID, der vedrører mindst én af de nedenfor anførte anvendelser: (1) At forøge forholdet mellem CD4+ CD25+ Treg-celler og CD4+T-celler; (2) At forbedre proliferationen af CD4+ CD25+ Treg-celler; (3) At forøge IL-10-sekretionen fra T-celler; (4) At regulere blodsukkeret hos TI D patienter; (5) At inhibere cytotoksicitetsvirkningen af auto-reaktive CD8+ T-celler; (6) At opregulere transkriptionsniveauet af IL-10 og/eller TGF-β i PBMC og/eller milt;
(7) At inhibere DC-modning;
(8) At formindske ekspressionen af mindst ét af proteinerne CD40, CD80, CD83, CD86 i DC.
DK13785267.9T 2012-04-13 2013-04-12 Farmaceutisk sammensætning til behandling og/eller forebyggelse af type i-diabetes og anvendelse deraf DK2842568T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210108159.6A CN103372214B (zh) 2012-04-13 2012-04-13 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用
PCT/CN2013/000429 WO2013163887A1 (zh) 2012-04-13 2013-04-12 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用

Publications (1)

Publication Number Publication Date
DK2842568T3 true DK2842568T3 (da) 2019-01-07

Family

ID=49458455

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13785267.9T DK2842568T3 (da) 2012-04-13 2013-04-12 Farmaceutisk sammensætning til behandling og/eller forebyggelse af type i-diabetes og anvendelse deraf

Country Status (5)

Country Link
US (1) US20150140007A1 (da)
EP (1) EP2842568B1 (da)
CN (2) CN106668852B (da)
DK (1) DK2842568T3 (da)
WO (1) WO2013163887A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327163B (zh) * 2014-09-28 2017-03-22 刘旭 胰岛素淀粉样多肽抑制剂及其制备方法、应用
WO2019002364A1 (en) * 2017-06-28 2019-01-03 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) METHOD OF DETERMINING THE RISK OF DEVELOPING TYPE 1 DIABETES
CN109970863A (zh) * 2017-12-28 2019-07-05 南京零一生物科技有限公司 一种具有降糖及免疫调节作用的双功能多肽及其用途
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN112933216B (zh) * 2019-12-24 2023-04-28 艾棣维欣(苏州)生物制药有限公司 同时含有胰岛素和地塞米松磷酸钠的稳定的药物组合物
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1
CN112426524A (zh) * 2020-12-21 2021-03-02 中国医学科学院生物医学工程研究所 植物性多糖作为佐剂在制备自身性免疫疾病药物中的应用
CN113925960B (zh) * 2021-08-31 2022-10-28 苏州尔生生物医药有限公司 一种预防或治疗i型糖尿病的疫苗系统及其制备方法
KR20240049848A (ko) * 2021-09-08 2024-04-17 인티그레이티드 나노테라퓨틱스 아이엔씨. 항원과 약물-지질 접합체의 면역조절 조합
CN115850486B (zh) * 2022-11-16 2023-05-30 艾可泰科(浙江)控股有限公司 胰岛干细胞在治疗糖尿病中的用途
CN116284391B (zh) * 2022-11-16 2023-08-08 艾可泰科(浙江)控股有限公司 使用胰岛干细胞和抗体治疗糖尿病

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
JP2008528043A (ja) * 2005-02-04 2008-07-31 ダウ・アグロサイエンシーズ・エルエルシー 抗ｔ細胞および自己免疫疾患の自己抗原治療
KR20100080519A (ko) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
CN101921325B (zh) * 2010-03-25 2012-06-27 南京医科大学 一种增加CD4+CD25+Foxp3+调节性T细胞的抗原及其应用

Also Published As

Publication number Publication date
WO2013163887A1 (zh) 2013-11-07
US20150140007A1 (en) 2015-05-21
CN106668852B (zh) 2020-12-25
CN106668852A (zh) 2017-05-17
EP2842568B1 (en) 2018-11-14
EP2842568A4 (en) 2016-03-30
CN103372214A (zh) 2013-10-30
CN103372214B (zh) 2017-09-29
EP2842568A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
DK2842568T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af type i-diabetes og anvendelse deraf
Stabler et al. Engineering immunomodulatory biomaterials for type 1 diabetes
US11253589B2 (en) Modulation of the immune response
Akdis et al. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases
Yaochite et al. Dynamic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis
Shen et al. Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptor
CN102449140B (zh) 抑制光感受器凋亡的方法
CN103917243A (zh) 基于pd-l1的免疫疗法
US20120076808A1 (en) Combined antigen and dna vaccine for preventing and treating autoimmune diseases
KR20100022022A (ko) 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
JP2007521019A (ja) 臓器再生方法
Villoslada et al. Immunotherapy for neurological diseases
Zhu et al. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Boettler et al. Immunotherapy of type 1 diabetes—how to rationally prioritize combination therapies in T1D
US20140286906A1 (en) Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
Preisser et al. Recombinant Lactococcus lactis Carrying IL‐4 and IL‐10 Coding Vectors Protects against Type 1 Diabetes in NOD Mice and Attenuates Insulitis in the STZ‐Induced Model
Maña et al. Demyelination caused by the copper chelator cuprizone halts T cell mediated autoimmune neuroinflammation
KR102025417B1 (ko) 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물
Huang et al. Advanced delivery strategies for immunotherapy in type I diabetes mellitus
Tang et al. Role of regulatory T cells in Schistosoma-mediated protection against type 1 diabetes
WO2014180269A2 (zh) 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
CN115697391A (zh) 改良的疫苗制剂
JP5815767B2 (ja) 免疫学的疾患の処置のためのチモシンα１の使用
Nabi-Afjadi et al. Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments
KR101711730B1 (ko) Dab2 유전자가 과발현된 수지상 세포를 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물